medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 1

<< Back

Medicina & Laboratorio 2022; 26 (1)

Prostate Health Index (phi)

Toro-Montoya AI, Vizcaíno-Carruyo JC, Guevara-Arismendy NM, Campuzano-Zuluaga G

Language: Spanish
References: 30
Page: 91-98
PDF size: 206.00 Kb.


Text Extraction

No abstract.


REFERENCES

  1. World Health Organization (WHO). Incidence,mortality and prevalence by cancersite. The Global Cancer Observatory (GLOBOCAN); 2020. p. 1-2. Acceso 06 de abril de2021. Disponible en https://gco.iarc.fr/today/data/factsheets/populations/170-colombiafact-sheets.pdf.

  2. Carroll PR, Parsons JK, Andriole G, BahnsonRR, Castle EP, Catalona WJ, et al. NCCN GuidelinesInsights: Prostate Cancer Early Detection,Version 2.2016. J Natl Compr Canc Netw2016;14:509-519. https://doi.org/10.6004/jnccn.2016.0060.

  3. Thompson IM, Ankerst DP, Chi C, Lucia MS,Goodman PJ, Crowley JJ, et al. Operatingcharacteristics of prostate-specific antigenin men with an initial PSA level of 3.0 ng/mlor lower. JAMA 2005;294:66-70. https://doi.org/10.1001/jama.294.1.66.

  4. National Comprehensive Cancer Network(NCCN). NCCN Clinical Practice Guidelinesin Oncology: Prostate cancer early detection.Plymouth Meeting, USA: 2018. p. 1-52. Acceso02 de abril de 2021. Disponible en https://www2.tri-kobe.org/nccn/guideline/urological/english/prostate_detection.pdf.

  5. Vukovic I, Djordjevic D, Bojanic N, Babic U,Soldatovic I. Predictive value of [-2]proPSA(P2PSA) and its derivatives for the prostatecancer detection in the 2.0 to 10.0ng/mL PSArange. International Braz J Urol 2017;43:48-56. https://doi.org/10.1590/S1677-5538.IBJU.2016.0256.

  6. White J, Shenoy BV, Tutrone RF, Karsh LI,Saltzstein DR, Harmon WJ, et al. Clinical utilityof the Prostate Health Index (phi) for biopsydecision management in a large group urologypractice setting. Prostate Cancer ProstaticDis 2018;21:78-84. https://doi.org/10.1038/s41391-017-0008-7.

  7. Boegemann M, Stephan C, Cammann H, VincendeauS, Houlgatte A, Jung K, et al. Thepercentage of prostate-specific antigen (PSA)isoform [–2]proPSA and the Prostate HealthIndex improve the diagnostic accuracy for clinicallyrelevant prostate cancer at initial andrepeat biopsy compared with total PSA andpercentage free PSA in men aged ≤65 years.BJU International 2016;117:72-79. https://doi.org/10.1111/bju.13139.

  8. Jain S, Pincus MR, Bluth MH, McPherson RA,Bowne WB, Lee P. Diagnosis and managementof cancer using serologic and other body fluidmarkers. In: Pincus MR, Bluth MH, McPhersonRA, Bowne WB, eds. Henry´s Clinical Diagnosisand Management by Laboratory Methods. 23rded. St. Louis: Elsevier; 2017. p. 1442-1444.

  9. Algeciras-Schimnich A. Insights: The ProstateHealth Index (phi) in prostate cancer riskassessment. Minnesota, USA: Mayo Clinic Laboratories;2017. Department of LaboratoryMedicine and Pathology. Acceso 11 de mayode 2021. Disponible en https://news.mayocliniclabs.com/2017/08/14/prostate-health-indexphi-prostate-cancer-risk-assessment-hot-topic/.

  10. Özen H, Sözen S. PSA isoforms in prostate cancerdetection. Eur Urol Supp 2006;5:495-499.https://doi.org/10.1016/j.eursup.2006.02.017.

  11. Filella X, Foj L, Alcover J, Augé JM, EscuderoJM, Molina R. ProPSA, un nuevo biomarcadorpara la detección y el manejo del cáncer depróstata. Rev Laboratorio Clín 2013;6:75-81.https://doi.org/10.1016/j.labcli.2013.01.006.

  12. Mikolajczyk SD, Marker KM, Millar LS, KumarA, Saedi MS, Payne JK, et al. A truncatedprecursor form of prostate-specific antigen is amore specific serum marker of prostate cancer.Cancer Res 2001;61:6958-6963.

  13. U.S. Food & Drug Administration. Quantitativetest for determination of [-2]proPSA levels.Silver Spring: FDA Summary of Safety and EffectivenessData; 2012. p. 1-32. Acceso 15 de mayode 2021. Disponible en https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090026b.pdf.

  14. Tosoian JJ, Druskin SC, Andreas D, MullaneP, Chappidi M, Joo S, et al. Use of the ProstateHealth Index for detection of prostate cancer:results from a large academic practice. ProstateCancer Prostatic Dis 2017;20:228-233. https://doi.org/10.1038/pcan.2016.72.

  15. Loeb S, Bruinsma SM, Nicholson J, BrigantiA, Pickles T, Kakehi Y, et al. Active surveillancefor prostate cancer: a systematic review ofclinicopathologic variables and biomarkers forrisk stratification. Eur Urol 2015;67:619-626.https://doi.org/10.1016/j.eururo.2014.10.010.

  16. de la Calle C, Patil D, Wei JT, Scherr DS,Sokoll L, Chan DW, et al. Multicenter evaluationof the Prostate Health Index to detectaggressive prostate cancer in biopsy naivemen. J Urol 2015;194:65-72. https://doi.org/10.1016/j.juro.2015.01.091.

  17. Osses DF, Remmers S, Schroder FH, van derKwast T, Roobol MJ. Results of prostate cancerscreening in a unique cohort at 19 yr of followup.Eur Urol 2019;75:374-377. https://doi.org/10.1016/j.eururo.2018.10.053.

  18. Abrate A, Lughezzani G, Gadda GM, Lista G,Kinzikeeva E, Fossati N, et al. Clinical use of[-2]proPSA (p2PSA) and its derivatives (%p2PSAand Prostate Health Index) for the detectionof prostate cancer: A review of the literature.Korean J Urol 2014;55:436-445. https://doi.org/10.4111/kju.2014.55.7.436.

  19. Heidegger I, Klocker H, Pichler R, PircherA, Prokop W, Steiner E, et al. ProPSA and theProstate Health Index as predictive markersfor aggressiveness in low-risk prostate cancerresultsfrom an international multicenter study.Prostate Cancer Prostatic Dis 2017;20:271-275.https://doi.org/10.1038/pcan.2017.3.

  20. Catalona WJ, Partin AW, Sanda MG, Wei JT,Klee GG, Bangma CH, et al. A multicenterstudy of [-2]pro-prostate specific antigen combinedwith prostate specific antigen and freeprostate specific antigen for prostate cancerdetection in the 2.0 to 10.0 ng/ml prostate specificantigen range. J Urol 2011;185:1650-1655.https://doi.org/10.1016/j.juro.2010.12.032.

  21. Shore ND, Pieczonka CM, Henderson RJ,Bailen JL, Saltzstein DR, Concepcion RS, etal. A comparison of prostate health index, totalPSA, %free PSA, and proPSA in a contemporaryUS population-The MiCheck-01 prospectivetrial. Urol Oncol 2020;38:683.e681-683.e610.https://doi.org/10.1016/j.urolonc.2020.03.011.

  22. Boegemann M, Arsov C, Hadaschik B,Herkommer K, Imkamp F, Nofer JR, et al.Discordant prostate specific antigen test resultsdespite WHO assay standardization. IntJ Biol Markers 2018;33:275-282. https://doi.org/10.1177/1724600818754750.

  23. Stephan C, Bangma C, Vignati G, BartschG, Lein M, Jung K, et al. 20-25% lower concentrationsof total and free prostate-specificantigen (PSA) after calibration of PSA assaysto the WHO reference materials--analysis of1098 patients in four centers. Int J Biol Markers2009;24:65-69.

  24. Vignati G, Giovanelli L. Standardization of PSAmeasures: a reappraisal and an experience withWHO calibration of Beckman Coulter AccessHybritech total and free PSA. Int J Biol Markers2007;22:295-301.

  25. Stephan C, Kopke T, Semjonow A, Lein M,Deger S, Schrader M, et al. Discordant totaland free prostate-specific antigen (PSA) assays:does calibration with WHO reference materialsdiminish the problem? Clin Chem Lab Med2009;47:1325-1331. https://doi.org/10.1515/CCLM.2009.285.

  26. Foj L, Filella X, Alcover J, Auge JM, EscuderoJM, Molina R. Variability of assay methods fortotal and free PSA after WHO standardization.Tumour Biol 2014;35:1867-1873. https://doi.org/10.1007/s13277-013-1249-2.

  27. Ferguson J, Atkinson E, Rigsby P, Burns C.WHO International Collaborative Study of theproposed 2nd WHO is for total PSA (PSA-ACT+ free PSA). Geneva, Switzerland: World HealthOrganization (WHO). Expert committee on biologicalstandardization; 2018. Acceso 03 deabril de 2021. Disponible en https://www.who.int/biologicals/BS.2018.2340_PSA_Total.pdf.

  28. Prostate Cancer UK. The test PSA. London, UK:Prostate Cancer UK; 2020. Acceso 19 de mayode 2021. Disponible en https://prostatecanceruk.org/prostate-information/prostate-tests/psa-test.

  29. Pagana KD, Pagana TJ. Mosby’s Manual ofDiagnostic and Laboratory Test. 4th ed. Misuri,USA; Mosby Elsevier; 2010.

  30. Bossens MM, Van Straalen JP, De Reijke TM,Kurth KH, Sanders GT. Kinetics of prostatespecificantigen after manipulation of the prostate.Eur J Cancer 1995;31a:682-685. https://doi.org/10.1016/0959-8049(95)00016-c.




2020     |     www.medigraphic.com